Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
Delayed Swiss Exchange  -  11:30:04 2023-02-03 am EST
0.0287 CHF   -0.69%
01/17RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
CI
01/17Relief Therapeutics Wins Review Board's Nod for Planned Clinical Study of Skin Cancer Drug
MT
01/17Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Relief Therapeutics' New Aviptadil Formulation Found To Be Stable In Six-month Data

11/07/2022 | 01:23am EST


ę MT Newswires 2022
All news about RELIEF THERAPEUTICS HOLDING AG
01/17RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial E..
CI
01/17Relief Therapeutics Wins Review Board's Nod for Planned Clinical Study of Skin Cancer D..
MT
01/17Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating R..
EQ
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVAfor Pati..
AQ
2022Acer Therapeutics' Olpruva Approved by FDA, Triggers Availability of $42.5 Million Loan
MT
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ ..
AQ
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of Olpruva™ f..
CI
2022Relief Therapeutics, Acer Therapeutics Win US FDA Nod For Urea Cycle Disorders Treatmen..
MT
2022Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 wit..
EQ
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ ..
EQ
More news
Financials
Sales 2022 12,0 M 13,0 M 13,0 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 126 M 137 M 137 M
Capi. / Sales 2022 10,5x
Capi. / Sales 2023 5,49x
Nbr of Employees 10
Free-Float 71,7%
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,03 CHF
Average target price 0,32 CHF
Spread / Average Target 1 029%
Managers and Directors
Jack M. Weinstein Chief Executive Officer
Jeremy Meinen Chief Financial Officer
Raghuram Selvaraju Chairman
Nermeen Varawalla Chief Medical Officer
Paolo Galfetti Chief Operating Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
RELIEF THERAPEUTICS HOLDING AG-4.33%137
MODERNA, INC.-3.55%66 559
LONZA GROUP AG21.92%44 368
IQVIA HOLDINGS INC.15.76%44 054
ALNYLAM PHARMACEUTICALS, INC.-1.80%28 711
SEAGEN INC.7.38%25 622